185 related articles for article (PubMed ID: 37055224)
1. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker B; Kratochwil C; Ahmadzadehfar H; Morgenstern A; Eiber M; Herrmann K; Pomykala KL
J Nucl Med; 2023 May; 64(5):685-692. PubMed ID: 37055224
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
Sun M; Niaz MJ; Niaz MO; Tagawa ST
Curr Oncol Rep; 2021 Mar; 23(5):59. PubMed ID: 33778927
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
5. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy.
Jadvar H; Colletti PM
J Nucl Med Technol; 2023 Mar; 51(1):16-21. PubMed ID: 36599704
[TBL] [Abstract][Full Text] [Related]
7. The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Filippi L; Chiaravalloti A; Schillaci O; Bagni O
Expert Rev Anticancer Ther; 2020 Oct; 20(10):823-829. PubMed ID: 32820953
[TBL] [Abstract][Full Text] [Related]
8. The application of theranostics in different stages of prostate cancer.
Alghazo O; Eapen R; Koschel S; Cumberbatch M; Buteau J; Loh R; Lawrentschuk N; Murphy DG
Future Oncol; 2021 Sep; 17(27):3637-3644. PubMed ID: 34227404
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
Ramnaraign B; Sartor O
Oncologist; 2023 May; 28(5):392-401. PubMed ID: 36806966
[TBL] [Abstract][Full Text] [Related]
10. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
11. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
12. Next generation radiotheranostics promoting precision medicine.
Pomykala KL; Hadaschik BA; Sartor O; Gillessen S; Sweeney CJ; Maughan T; Hofman MS; Herrmann K
Ann Oncol; 2023 Jun; 34(6):507-519. PubMed ID: 36924989
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
15. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
Patel CM; Wadas TJ; Shiozawa Y
Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
[TBL] [Abstract][Full Text] [Related]
16.
Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
[TBL] [Abstract][Full Text] [Related]
17. Molecular radiotheragnostics in prostate cancer.
Du Y; Dizdarevic S
Clin Med (Lond); 2017 Oct; 17(5):458-461. PubMed ID: 28974599
[TBL] [Abstract][Full Text] [Related]
18. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
19. Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.
Manogue CE; Chen W; Mazza A; Dang A; Lewis B; Wallis CJD; Layton J; Barata P; Sartor O; Harris KM
Pract Radiat Oncol; 2022; 12(4):300-304. PubMed ID: 35717044
[TBL] [Abstract][Full Text] [Related]
20. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
